Coverage
-
March 24, 2022
Endo Pharmaceuticals on Thursday secured a D.C. federal court's dismissal of the Federal Trade Commission's antitrust suit accusing it of entering a second "pay-for-delay" agreement with Impax Laboratories to stave off competition to Endo's Opana ER painkiller.
3 other articles on this case.
View all »